Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chattem ephedra

This article was originally published in The Tan Sheet

Executive Summary

Roughly $2 mil. to $2.5 mil. in ephedra-containing Dexatrim remained on retail shelves as of March, although all such products "should be off shelves by May," Chattem tells investors April 3 at Banc of America Securities Consumer Conference. Chattanooga, Tenn.-based firm took $750,000 hit in Q1 to replace product with new formulation, execs add. Despite charge, first quarter revenue reached $58.4 mil., a 20.7% increase over year-ago period, attributable in part to growing Selsun Blue sales (1"The Tan Sheet" March 24, 2003, In Brief)...

You may also be interested in...

Chattem Icy Hot ads

Q3 launch of Icy Hot Back Patch will be supported with $12 mil. TV, print ad campaign featuring Los Angeles Lakers basketball star Shaquille O'Neal; initiative is expected to spur topical analgesic sales growth in second half, President & COO Alec Taylor says during March 20 analysts call. Chattem has said the line extension could generate annual sales of $6 mil.-$8 mil. (1"The Tan Sheet" Jan. 27, 2003, p. 6). Firm's Q1 revenue jumps 20.7% to $58.4 mil., bolstered by 38% rise in Selsun Blue sales, along with double-digit gains by Icy Hot, pHisoderm, Garlique, Chattanooga, Tenn.-based firm reports. International revenues leap 89% in first quarter, "led by sales of Selsun Blue and the continuing strength of Gold Bond in Canada." Chattem's net income reached $4.6 mil. versus a loss of $6.5 mil. in year-ago period...

Triptan Switches Offer Hope For Australia’s OTC Market

Switch expert Natalie Gauld says recent triptan switch recommendations signal a turnaround for Australia's OTC market.

Bharat Biotech Plans Coronavirus Vaccine

After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts